Neeha Zaidi

“We thought if we can see an immune response in patients with cancer, the vaccine should work even better in people who are at higher risk because of a family history, gene alteration or cyst on the pancreas,”

Neeha Zaidi · said date not stated · reported 2026-07-17

Zaidi explains the rationale for testing the vaccine in high-risk individuals after seeing immune responses in cancer patients.

“In addition, the vaccine was safe and well tolerated, supporting its use in larger cancer interception studies.”

Neeha Zaidi · said date not stated · reported 2026-07-17

Zaidi states the vaccine was safe and well tolerated, supporting larger interception studies.

“Individuals at high risk due to hereditary predisposition or to the presence of a concerning pancreatic lesion detected on imaging usually undergo surveillance to monitor for changes over time,”

Neeha Zaidi · said date not stated · reported 2026-07-17

Zaidi explains that high-risk individuals typically undergo surveillance to monitor for changes before surgical resection is considered.

“This long-lasting response is particularly noteworthy when assessing for possible interception of cancer, which requires long-lasting immunity,”

Neeha Zaidi · said date not stated · reported 2026-07-17

Zaidi notes that the long-lasting immune response is important for cancer interception, which requires durable immunity.

“If there is a high enough concern for transformation to cancer or if early cancer is detected, the current standard of care is surgical resection. However, the chances of recurrence are up to 80%, and many precursor lesions to pancreatic cancer are microscopic and thus undetectable by imaging.”

Neeha Zaidi · said date not stated · reported 2026-07-17

Zaidi describes the current standard of care and the high recurrence rate of up to 80% after surgical resection.